Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
Bio Pharma Dive
JUNE 7, 2022
The two biotechs will use gene editing to make prospective treatments more potent, adding to a recent flurry of activity involving the fast-emerging form of cellular immunotherapy.
Let's personalize your content